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A B S T R A C T
From the Croatian Cancer Registry (period 1991–1997) 194 malignant pleural mesothelioma patients were collected.
According to participation in polio vaccination mass campaign in 1961 that covered the entire Croatian population aged
3 months to 20 years, mesothelioma patients were divided in vaccinated (N=58), and non-vaccinated (N=136) subjects.
Significantly higher percentage of those with a history of occupational exposure to asbestos was found in vaccinated
(79%) compared to non-vaccinated group (63%). This is the opposite to what would be expected if potential SV40 contami-
nation of polio vaccine used had a causative role in the development of the tumour. On the other hand, shorter latency pe-
riod reflected by very high percentage of 45-year-old or younger mesothelioma patients in vaccinated group (15 out of 58),
with all of them having a history of occupational asbestos exposure, raises a question for a possible enhancing effect of the
vaccine used to asbestos exposure, if it was contaminated with SV40.
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Introduction
Since the link between malignant pleural mesothelio-
ma and asbestos was first suggested in South African as-
bestos miners1, exposure to asbestos has been considered
as the main etiological factor in the development of this
tumour. Simian virus 40 (SV40), as another potential fac-
tor, came into focus of attention when it was discovered
as a contaminant of poliovirus vaccines in the early
1960s. It may be assumed that between 1955 and the be-
ginning of year 1963 millions of subjects throughout the
world had been treated with contaminated vaccines.
About 98 millions children and adults received inactiva-
ted polio-vaccine in USA during that period. The propor-
tion that was actually infected by SV40 was estimated at
10% to 30%2. Although cell culture and animal studies
argued against a role for SV40 in human disease, recen-
tly a number of reports have implicated SV40 in the aeti-
ology of 40% to 60% of human mesotheliomas, based on
detection of DNA sequences encoding the SV40 large – T
antigen and/or its protein expression in such tumours3–7.
In 2005 an article was published with evidence against a
role for SV40 in human mesothelioma8. In that study,
none of 69 tumours, in which a single copy gene was rea-
dily amplified, contained detectable SV40. Kidney, a
known reservoir of SV40 in monkeys, from some of these
individuals was also negative for SV40 large – T antigen
sequences. In a more recent study on the frequency of
SV40 infection in Japanese malignant mesothelioma ca-
ses, the presence of SV40 large T antigen in 35 mesothe-
lioma samples was not found, as well9. Nevertheless, epi-
demiological evidence in literature regarding the associa-
tion between SV40 and the occurrence of mesothelioma
is rather limited. Only a few period-cohort studies were
carried out, either on mortality or incidence rates of can-
cer in the search for an effect due to treatment with po-
lio-vaccine in 1955–196310–12. In these studies no signifi-
cant increase in the occurrence of mesothelioma has
been observed.
Some years ago we performed a study on malignant
pleural mesothelioma in Croatia, its geographical distri-
bution, and the occupations of the patients13. Age-stan-
dardized incidence rates (period 1991–1997) was 0.74/
100,000 (men 1.34 and women 0.27). Recorded cases of
mesothelioma ranged from 20 in 1991, 23 in 1992, 37 in
1993, and 34 in 1994, up to 43 in 1995, 48 in 1996, and 43
in 1997. About two-thirds of patients with this tumour
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were occupationally exposed to asbestos. The remaining
third of patients, whose occupation was not related to as-
bestos exposure, still had the tumour incidence about
two per million per year. An explanation of this finding
could be in non-occupational exposure to asbestos. How-
ever, there was also a possibility of involvement of SV40
as one of the etiological factor. Namely, the incidence of
poliomyelitis in Croatia had progressively increased since
1945. There were serious epidemics with 388 cases in
1953, and 563 in 1960. In order to protect the age groups
of greatest risk a mass vaccination campaign was carried
out with Koprowski live virus vaccine in the early spring
of 1961, covering the entire population aged 3 months to
20 years14. Altogether 1,339,244 persons were given type
1 (CHAT strain), and 1,287,909 received type 3 (W-Fox).
During this first phase of vaccination against polio there
was a possibility of SV40-contamination of polio-vaccine
used, although this could not be confirmed at that time.
Later than 1963, measures were applied to prevent the
contamination of vaccines with SV40.
The purpose of this study was to evaluate the role of
poliovirus vaccine used, potentially contaminated with
SV40, in the development of mesothelioma.
Subjects and Methods
The study was performed in 194 subjects with malig-
nant pleural mesothelioma recorded by the Croatian
Cancer Registry over seven years (1991–1997). With the
use of a short questionnaire sent to the patients’ families
additional information on their occupation (possible ex-
posure to asbestos) were obtained. In the study were in-
cluded only registered patients with the tumour for
whom the additional questionnaire was answered: 194
out of 248 malignant pleural mesothelioma patients re-
corded by the Registry (78% response).
In connection with the mentioned mass vaccination
campaign with polio-vaccine potentially contaminated
with SV40 carried out in 196114, subjects selected for the
study were divided into two groups. One group consisted
of 58 subjects whose age ranged between 3 months and
20 years at the time of vaccination. As vaccination was
compulsory, it is reasonable to assume that they received
vaccine against poliovirus. The other group consisted of
136 non-vaccinated subjects who were older than 20
years of age at the time of vaccination campaign.
Results
In the group of vaccinated during the mass vaccina-
tion campaign in 1961, out of 58 subjects only 6 (10.3%)
were women and 52 (89.7%) men. Median age of vaccina-
ted patients was 48,5 years (range 35–56 years).
In the group of non-vaccinated patients there were 36
(26.5%) women and 100 men (73.5%). Median age was 64
years (range 53–84 years).
Table 1 shows the proportion of asbestos-exposed sub-
jects by age in vaccinated and non-vaccinated groups.
Of all subjects in the vaccinated group, 15 (28.8 %)
were younger than 45 years, and all had a history of occu-
pational exposure to asbestos. The youngest patient was
a 35-year-old man. Based on the questionnaire data, he
had a history of occupational exposure in an asbestos
processing plant in another country. Among the youngest
patients, a 38-year-old man had been engaged in mac-
hine maintenance on ships. Other patients from the vac-
cinated group younger than 45 years were exposed to as-
bestos in shipbuilding industry (3 workers), asbestos-ce-
ment industry (3 workers), insulation and asbestos tex-
tile industry (4 workers), and in construction industry (3
workers).
In the non-vaccinated group the youngest patient was
a female administrative worker (aged 53) without the
history of occupational exposure to asbestos. Table 2 and
3 show the occupation of vaccinated and non-vaccinated
subjects with pleural mesothelioma, according to the
questionnaire.
As seen from Table 2, among vaccinated subjects only
one women (out of 6) had a work history with exposure to
asbestos, while 45 men – including 8 construction workers
– were occupationaly exposed to asbestos. In the non-vac-
cinated group 8 women (out of 36) and 77 men – includi-
ng 20 construction workers – (out of 100) were exposed
to asbestos (Table 3).
Comparison between the analysed groups, taking
men and women together, shows that in vaccinated sub-
jects there was significantly higher percentage of those
with a history of occupational exposure to asbestos (in-
cluding presumably asbestos-exposed in construction in-
dustry) than in non-vaccinated subjects (79%:63%; Chi
square=4.44; p=0.0351). Presumably exposed to asbes-
tos in construction industry, due to increased use of as-
bestos-based construction material, were similarly distri-
buted in both groups compared (14%:15%). When con-
struction industry workers in both vaccinated and non-
-vaccinated groups were excluded, the difference was still
significant (Chi square=4.33; p=0.0376).
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VACCINATED AND NON-VACCINATED SUBJECTS EXPOSED TO















Higher percentage of patients whose occupation was
not related to asbestos exposure was observed in non-
-vaccinated (37%) than in vaccinated group (21%).
Discussion
As shown in the results, vaccinated subjects had signi-
ficantly higher percentage of those with a history of occu-
pational exposure to asbestos when compared to no-
n-vaccinated subjects. On the other hand, in subjects
whose occupation was not related to asbestos exposure,
higher participation in non-vaccinated than in vaccina-
ted group was observed. These findings do not indicate a
causative role of potentially SV40-contaminated polio-
-vaccine used. However, another explanation could lie in
non-occupational exposure to asbestos, as pointed ear-
lier. Our previous studies15, 16 indicated the importance of
asbestos emissions in the environment around asbestos
processing and asbestos-cement plants for the develop-
ment of lung tumours, including pleural mesothelioma.
Environmental exposure to asbestos may also be invol-
ved in enhancing the risk of respiratory tract tumours,
particularly in jobs involving outdoor work (agriculture,
construction) in areas contaminated by asbestos emitted
from industrial sources. Housewives involved in farming
or gardening, which is rather common in the areas with
asbestos processing and asbestos-cement plants, were al-
so among them. Our study of the incidence of malignant
plural mesothelioma in coastal and continental Croatia13
shows that standardized incidence of this tumour by resi-
dence and sex was 0.38/100,000 for women in the coastal
area, while in the continental area it was 0.24/100,000,
and in the city of Zagreb 0.18/100,000, but these differen-
ces were not statistically significant. Exposure to non-i-
dentified or less identified sources of asbestos has also to
be considered. For example, the same study showed that
age-standardized incidence of malignant pleural mesot-
helioma in males, was only slightly (with marginal signif-
icance) higher in the coastal area with numerous identi-
fied exposure sources of asbestos than in the city of
Zagreb, as a large urban area without particularly identi-
fied sources of exposure to asbestos.
Our results show that, apart from age differences in
tumour cases, there was also a gender difference. Among
those who had asbestos exposure history in the vaccina-
ted group, there was only one woman out of six with me-
sothelioma. In the non-vaccinated group, 10 of 36 women
had a history of occupational exposure to asbestos. This
ratio is closer to the ratio of tumour incidence generally
observed in earlier studies13, which is approximately four
times higher in men than in women. It may be worth to
note that before asbestos ban, certain jobs in shipbuild-
ing and asbestos-cement industry, which were important
sources of occupational exposure to asbestos, were occu-
pied almost exclusively by men.
Although a causative role of polio-vaccine potentially
SV40-contaminated could not be implied by our data, in-
teresting observation regarding age, and consequently
M. [ari} et al.: Polio-Vaccine and Pleural Mesothelioma, Coll. Antropol. 32 (2008) 2: 479–483
481
TABLE 2











Women 0 0 1 0 1 4 6
Men 13 7 17 8 0 7 52
Total 13 7 18 8 1 11 58
*Insulation workers (n=1), asbestos processing (n=7), asbestos textile workers (n=4), maintenance and repair of machines and items
containing asbestos (n=3), naval machinists (n=1), history of work in asbestos processing plant abroad (n=1), transportation and
storage of asbestos (n=1)
†Blue collar workers (n=2), technicians (n=1), administrative staff (n=2), persons with university education (n=1), miscellaneous
(n=2), housewives (n=3)
TABLE 3










Women 2 0 8 0 9 17 36
Men 41 5 11 20 8 15 100
Total 43 5 19 20 17 32 136
*Insulation workers (n=4), asbestos processing (n=1), asbestos textile workers (n=2), maintenance and repair of machines and items
containing asbestos (n=1), history of work in asbestos processing plant abroad (n=3), naval machinists (n=2), transportation and
storage of asbestos (n=5), asbestos-cement workers wife (n=1)
†Blue collar workers (n=7), technicians (n=1), administrative staff (n=8), persons with university education (n=3), miscellaneous
(n=2), housewives (n=11)
latency period for the onset of the disease, has to be poin-
ted out. It is known that higher cumulative exposure to
asbestos generally correlates with the increased risk of
malignant mesothelioma, although studies have revealed
that the tumour may develop from short-term exposure
and lower exposure levels, as well18. Supporting this gen-
erally accepted experience is a study on patients with ma-
lignant pleural mesothelioma treated between 1991–2000
at the Split University Hospital17. It showed that only
5.6% of patients developed mesothelioma after 10–20
years of exposure, 9.9% after 21–30 years of exposure,
while 85.5% developed the tumour after 31–40 years of
exposure or even longer. Coming back to age and latency
period, in a study on 343 mesothelioma cases in Croatia
for a period of 10 years (1989–1998) which included 194
subjects dealt in our study, 7.8% of the total number of
registered patients were 44 years old or younger19. On
the other hand, a study performed in Australia for a
three year period (1997–1999), significantly lower per-
centage of mesothelioma patients in the same age group
was registered, that is 1.8% to 2.6% out of total number
of registered mesothelioma patients20. In a study on the
incidence of malignant mesothelioma (period 1980–1990)
performed in the province of Brescia (Italy), out of 190
cases registered only 10 (5.2%) were younger than 45
years, with only one subject occupationally exposed to as-
bestos21. In a study on mesothelioma epidemic in West-
ern Europe during the period 1990–1999 which dealt wi-
th males only, in the age group of 40 to 54 years the
number of deaths from pleural cancer, expressed as per-
cent from total number of pleural cancer deaths in accor-
ding country, ranged between 10.6% to 13.1% (France
10.6%, Italy 11.6% and Germany 13.1%)22. For compari-
son, in our present study we found even 29% of mesothe-
lioma patient of the same age group. The increase in me-
sothelioma incidence during the period of observation,
namely in the years 1993–1997, as noted in the Introduc-
tion, could be at least partly explaned by increase of tu-
mours in younger subjects with shorter exposure to as-
bestos involved in tumour development.
Since all of our mesothelioma patients younger than
45 years (15 out of 58 vaccinated) were vaccinated with
incriminated polio-vaccine, and all of them had a history
of occupational asbestos exposure, a question may be rai-
sed for a possible enhancing effect of SV40 and asbestos
in development of mesothelioma. Hypothetically, there is
a possibility that SV40 acts as a co-carcinogen to asbestos
in the occurrence in human mesothelioma. In some of
the published observations such an assumption has been
mentioned4. A recently published molecular epidemiolo-
gic case-control study23, which following such assump-
tion has to be emphasized, was dealing with the hazard
ratio of developing mesothelioma in exposure to asbestos
alone, SV40 alone, and to asbestos exposure plus SV40
infection. Asbestos exposure alone was associated with
mesothelioma, while SV40 alone was not. The contami-
nation with SV40 plus asbestos exposure revealed signifi-
cantly greater risk of developing mesothelioma compared
to asbestos exposure alone.
Conclusion
Although a number of cases of malignant pleural me-
sothelioma cannot be etiologically explained, the results
of this epidemiologic observation do not suggest a causa-
tive role of potentially SV40-contaminated polio-vaccine
used. However, based on high percentage of mesothelio-
ma patients younger than 45 years in our study, with all
of them being vaccinated with polio-vaccine potentially
contaminated with SV40 and having a history of occupa-
tional exposure to asbestos, a question may be raised for
a possible enhancing effect of SV40 and asbestos in devel-
opment of mesothelioma. Nevertheless, the lack of evi-
dence concerned with the contamination of the vaccines
used does not allow a firm conclusion.
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ULOGA POLIOVAKCINE U NASTANKU MEZOTELIOMA POPLU]NICE
– EPIDEMIOLO[KO OPA@ANJE
S A @ E T A K
Godine 1961. provedeno je u Hrvatskoj masovno cijepljenje protiv poliovirusa, kojim je bila obuhva}ena cijela popu-
lacija u dobi od 3 mjeseca do uklju~ivo 20 godina `ivota. Da bi se ispitala mogu}a veza izme|u upotrebljenog cjepiva i
razvoja malignog mezotelioma poplu}nice, iz podataka Hrvatskog registra za rak (razdoblje 1991.–1997.) izdvojene su
194 osobe s mezoteliomom od kojih su 58 bile cijepljene 1961. godine, a 136 su bile necijepljene. Temeljem podataka do-
bivenih anketom (heteroanamneza), u skupini cijepljenih registriran je zna~ajno ve}i postotak osoba, koje su bile profe-
sionalno izlo`ene azbestu u odnosu na necijepljene (79% : 63%). Takav nalaz govori protiv pretpostavljene uloge prove-
dene vakcinacije u razvoju mezotelioma. Me|utim, u skupini cijepljenih s mezoteliomom 15 (od ukupno 58) bili su
mla|i od 45 godine s time {to su svi bili profesionalno izlo`eni azbestu. Znatno kra}e latentno razdoblje od o~ekivanog u
tih cijepljenih osoba ujedno izlo`enih azbestu, upu}uje na mogu}nost da je kori{teno cjepivo pridonjelo razvoju tumora.
Sigurniji zaklju~ak, ipak, nije mogu} budu}i da ne raspola`emo podatkom da li je upotrebljeno cjepivo bilo doista one-
~i{}eno virusom SV40.
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